Yu L, Bischof E, Lu HH. Anesthesia with ciprofol in cardiac surgery with cardiopulmonary bypass: A case report. World J Clin Cases 2023; 11(1): 157-163 [PMID: 36687195 DOI: 10.12998/wjcc.v11.i1.157]
Corresponding Author of This Article
Hui-Hong Lu, MM, Associate Chief Physician, Department of Anesthesiology, Shanghai East Hospital of Tongji University, No. 150 Jimo Road, Pudong New Area, Shanghai 200120, China. 826601285@qq.com
Research Domain of This Article
Anesthesiology
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Jan 6, 2023; 11(1): 157-163 Published online Jan 6, 2023. doi: 10.12998/wjcc.v11.i1.157
Anesthesia with ciprofol in cardiac surgery with cardiopulmonary bypass: A case report
Le Yu, Evelyne Bischof, Hui-Hong Lu
Le Yu, Department of Anesthesiology, East Hospital, Tongji University School of Medicine, Shanghai 200120, China
Evelyne Bischof, Laboratory of Tumor Molecular Biology, School of Basic Medical Sciences, Shanghai University of Medicine and Health Sciences, Shanghai 201318, China
Hui-Hong Lu, Department of Anesthesiology, Shanghai East Hospital of Tongji University, Shanghai 200120, China
Author contributions: Yu L and Lu HH participated in the anesthesia management of the present case, and both were the major contributors of this manuscript; Bischof E helped revise the manuscript; all authors read and approved the final manuscript.
Informed consent statement: Informed written consent was obtained from the patient for publication of this report and any accompanying images.
Conflict-of-interest statement: The authors declare that they have no conflict of interest to disclose.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Hui-Hong Lu, MM, Associate Chief Physician, Department of Anesthesiology, Shanghai East Hospital of Tongji University, No. 150 Jimo Road, Pudong New Area, Shanghai 200120, China. 826601285@qq.com
Received: August 23, 2022 Peer-review started: August 23, 2022 First decision: October 28, 2022 Revised: November 12, 2022 Accepted: December 15, 2022 Article in press: December 15, 2022 Published online: January 6, 2023 Processing time: 134 Days and 15.6 Hours
Abstract
BACKGROUND
Ciprofol is a novel agent for intravenous general anesthesia. In February 2022, it was approved by the National Medical Products Administration for general anesthesia induction and maintenance. It has the advantages of fast onset, fast elimination, stable circulation, and few adverse reactions. However, the efficacy and safety of ciprofol in cardiac surgery with cardiopulmonary bypass have not been reported. Here we describe a case where ciprofol was successfully used for anesthesia in cardiac surgery with cardiopulmonary bypass.
CASE SUMMARY
A 72-year-old man (height 176 cm; weight 70 kg) was diagnosed with coronary atherosclerotic cardiomyopathy requiring coronary artery bypass grafting and left ventricular aneurysmectomy. Ciprofol was administered for induction (0.4 mg/kg) and maintenance (0.6-1.0 mg/kg/h) of general anesthesia. During the entire operation, the bispectral index, hemodynamics, and blood oxygen saturation were maintained at normal levels. The patient recovered well after surgery, with no serious adverse events related to ciprofol.
CONCLUSION
Ciprofol is safe and effective for anesthesia in cardiac surgery with cardiopulmonary bypass.
Core Tip: Ciprofol is a novel agent for intravenous general anesthesia. It is characterized by fast onset, fast elimination, stable circulation, and few adverse reactions. This is the first case report of ciprofol administration for anesthesia in cardiac surgery with cardiopulmonary bypass. Based on our experience in this case, we conclude that ciprofol is safe and effective for anesthesia in cardiac surgery with cardiopulmonary bypass. With further testing, ciprofol may replace propofol in the field of anesthesia for cardiac surgeries.
